Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocontrol Technology

This article was originally published in The Gray Sheet

Executive Summary

FDA will purchase one of the firm's Diasensor 1000 noninvasive blood glucose monitors, as the agency looks to "gain knowledge of the performance of such devices over their full range of performance," the company reports Feb. 9. The firm says it plans to "conduct a seminar to educate the FDA staff on the use and maintenance of this particular instrument so they can evaluate its performance characteristics and conduct laboratory research on noninvasive monitoring." Biocontrol has not yet resubmitted its 510(k) for the system since FDA's decision to withhold approval until further data on home use is collected
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel